Monograph Details
|
|
Neoplasms
> Cytotoxic antibiotics
|
|
ZANOSAR |
| Manufacturer |
|
Teva Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Anthracycline (nitrosourea). |
| Generic Name |
|
Streptozocin 1g/vial; pwd for IV inj or infusion after reconstitution/dilution; preservative-free. |
| Indications |
|
Symptomatic or progressive metastatic pancreatic islet cell cancer. |
| Children |
|
Not recommended. |
| Adults |
|
1g/m2 IV once weekly for 2 weeks; may repeat weekly; max 1.5g/m2 per dose. Or, 500mg/m2 IV daily for 5 days every 6 weeks until max benefit or toxicity. |
| Precautions |
|
Renal dysfunction or disease. Monitor renal function (eg, urinalysis, BUN, creatinine, electrolytes) before, weekly during, and for 4 weeks after therapy; discontinue or reduce dose if significant renal toxicity occurs (see literature). Obtain CBCs, liver function tests weekly. Avoid extravasation. Ensure adequate hydration. Elderly. Pregnancy (Cat.D). Nursing mothers: not recommended. |
| Interactions |
|
Avoid concomitant nephrotoxic agents. Additive toxicity with other cytotoxic drugs. Severe bone marrow toxicity with doxorubicin. Phenytoin may reduce cytotoxicity. |
| Adverse Reactions |
|
GI upset (may be severe); hematological, hepatic and renal (cumulative and dose-related; may be fatal) toxicity; glucose intolerance, nephrogenic diabetes insipidus, inj site reactions, CNS effects (eg, confusion, lethargy, depression). |
| How Supplied |
|
Single-use vial—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
